Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS trial.
Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML
Revisit the OncLive On Air Episodes From February 2024
Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection
FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease
NK Cell Therapy IGNK001 Receives FDA Orphan Drug Designation for AML
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC